PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
This is a prospective single-arm, multicenter, phase Ib/II clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.
Peripheral T-Cell Lymphoma
DRUG: Parsaclisib|DRUG: Chidamide
objective response rate, the total proportion of patients with complete response (CR) and partial response (PR), every 8 or 12 weeks from the day of the first cycle to 2 years after the last patient's enrollment (each cycle is 28 days).
2-year progression-free survival, the total proportion of patients with no progression from date of the first day of treatment to the date of confirmed progressive disease or death which one occurs first, from the day of the first cycle of treatment to the date of confirmed progressive disease or death, whichever occurs first, up to 2 years after last patient's enrollment (each cycle is 28 days).|2-year overall survival, from date of first day of treatment to the date of death by any cause, from date of the first cycle of treatment to the date of death from any cause, assessed up to 2 years after last patient's enrollment (each cycle is 28 days).|incidence and relationship with study drugs of grade 3-4 adverse events, the incidence and relationship with study drugs of grade 3 or 4 adverse events (based on NCI CTC-AE v4.03, from the date of the first cycle of treatment to 2 years after last patient's enrollment (each cycle is 28 days).
This is a prospective single-arm, multicenter, phase Ib/II clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.